# ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. As necessary, this list will be updated with the posting of monthly errata reports on www.usp.org/USPNF/newOfficialTextand in every issue of *PF*. This information will also be available as a cumulative table in future *Supplements*, and will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

| ***USP32–NF27*** | | | |
|---|---|---|---|
| **Page** | **Title** | **Section** | **Description** |
| 1679 | *Biotin* | *Chemical Formula* | Change "1*H*-Thieno3,4-*d*imidazole-4-pentanoic acid, hexahydro-2-oxo-, 3a*S*-(3aα,4*β*,6aα)-. (3a*S*,4S,6a*R*)-Hexahydro-2-oxo-1*H*-thieno3,4-*d*imidazole-4-valeric acid [*58-85-5*]. " to: 1*H*-Thieno[3,4-*d*]imidazole-4-pentanoic acid, hexahydro-2-oxo-, [3a*S*-(3aα ,4*β*,6aα)]-. (3a*S*,4S,6a*R*)-Hexahydro-2-oxo-1*H*-thieno[3,4-*d*]imidazole-4-valeric acid [*58-85-5*]. |
| 1685 | *Bismuth Subcarbonate* | *Limit of lead* | Line 12 under *Procedure*: Change "*C* / 12,500." to: *C* / 1250. |
| 1943 | *Ciprofloxacin Ophthalmic Ointment* | *Assay* | Line 7–8 under *Procedure*: Change "(331.34 / 385.82)(25*C* / *W*)($r_U$ / $r_S$) in which 331.34 and 385.82 are the molecular weights of ciprofloxacin and ciprofloxacin hydrochloride monohydrate, respectively;" to: (331.34 / 367.81)(25*C* / *W*)($r_U$ / $r_S$) in which 331.34 and 367.81 are the molecular weights of ciprofloxacin and anhydrous ciprofloxacin hydrochloride, respectively; |
| 1958 | *Clarithromycin for Oral Suspension* | *USP Reference standards* ⟨11⟩ | Delete "*USP Clarithromycin Related Compound A RS*." |
| 2828 | *Magnesia Tablets* | *Assay* | Line 4: Change "flask, and proceed as directed in the *Assay* under *Milk of Magnesia* beginning with "Dissolve in 10 mL of 3 N hydrochloric acid."" to: flask. Dissolve in 10 mL of 3 N hydrochloric acid, dilute with water to volume, and mix. Proceed as directed in the *Assay* under *Milk of Magnesia* beginning with "Filter, if necessary, and transfer 25.0 mL of the filtrate." |
| 2863 | *Medroxyprogesterone Acetate Injectable Suspension* | *Assay* | Line 3 under *Chromatographic system*: Change "The flow rate is about 2 mL per minutes." to: The *Mobile phase* is maintained at a flow rate capable of giving the required resolution and suitable elution times. |
| | | | Line 1 under *Procedure*: Change "Proceed as directed in the *Assay* under *Medroxyprogesterone Acetate*." to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. |
| 3896 | *Zinc Oxide Neutral* | *Mercury* | Line 2 under *Standard solutions*: Change "*Standard stock mercury solution*" to: *Standard working mercury solution* |
| ***First Supplement to USP32–NF27*** | | | |
| 4104 | *Trandolapril* | *Related compounds* | Table under *Procedure*: Change the Relative Response Factor (*F*) of Trandolapil related compound $C^1$ "2.2" to: 0.45 |

| ***USP32–NF27*** **Page** | **Title** | **Section** | **Description** |
|---|---|---|---|
| ***Second Supplement to USP32–NF27*** | | | |
| 4175 | ⟨1090⟩ *Assessment of Drug Product Performance—Bioavailability, Bioequivalence and Dissolution* | *Introduction* | Delete the Introductory paragraph. |

| ***USP33–NF28 Reissue*** **Page** | **Title** | **CATEGORY** **Section** | **Description** |
|---|---|---|---|
| R-76 | ⟨711⟩ *Dissolution* | *Apparatus* | Replace the drawing for *Figure 2a* as shown at the end of this table. |
| R-431 | *Polysorbate 80* | IMPURITIES Organic Impurities Procedure: Ethylene Oxide and Dioxane | Line 13 under *Analysis*: Change "$C_D$ = concentration of dioxane in *Sample solution A* (µg/mL)" to: $C_D$ = concentration of dioxane in *Sample solution B* (µL/mL) |
| R-491 | *Losartan Potassium and Hydrochlorothiazide Tablets* | ASSAY Procedure | Under *Standard solution*, last row last column of table: Change "01" to: 0.1 |
| | | | Under *Sample solution*, last row last column of table: Change "01" to: 0.1 |
| R-504 | *Methylcellulose* | IDENTIFICATION E. Procedure | Line 2under *Analysis*: Change "obtained in *Identification* test *A*" to: obtained in *Identification* test *B* |
| R-523 | *Oxaliplatin for Injection* | IMPURITIES Organic Impurities Procedure 3: Limit of Related Compound C and Unspecified Impurities | Line 2 under *Relative standard deviation*: Change "oxalic acid and oxaliplatin related compound C peaks" to: oxaliplatin and oxaliplatin related compound C peaks |
| R-532 | *Pyrantel Pamoate* | IMPURITIES Organic Impurities Procedure | Line 13 under *Analysis*: Change "$r_S$ = peak response for pyrantel related compound A from the *Standard solution*" to: $r_S$ = peak response for pyrantel related compound A from the *System suitability solution* |
| R-547 | *Tranexamic Acid* | IMPURITIES Inorganic Impurities Chloride and Sulfate, *Chloride* ⟨221⟩ | Line 1: Change "A 0.36-g portion" to: A 0.51-g portion |
| R-558 | *Vincristine Sulfate Injection* | IMPURITIES Organic Impurities Procedure | Line 6 under *Analysis*: Change "$r_U$ = peak response for each impurity from *Sample stock solution*" to: $r_U$ = peak response for each impurity appearing after the solvent peak from *Sample stock solution* |
| ***First Supplement to USP33–NF28 Reissue*** | | | |
| R-921 | *Irinotecan Hydrochloride* | IMPURITIES Organic Impurities Procedure 1: Limit of Irinotecan Hydrochloride Enantiomer | Lines 1–4: Change "**Mobile phase**: Hexane, alcohol, and diethylamine (250 : 250 : 1) **Diluent**: Alcohol and diethylamine (250 : 1)" to: **Mobile phase**: Hexane, dehydrated alcohol, and diethylamine (250 : 250 : 1) **Diluent**: Dehydrated alcohol and diethylamine (250 : 1) |
| R-982 | *Telmisartan* | IMPURITIES Organic Impurities Procedure | In *Impurity Table 1*, under column Relative Retention Time: Change row 2 Telmisartan amide[b] "0.67" to: 0.7 |
| | | | In the same table and column: Change row 4 Telmisartan diacid[d] "1.1" to: 0.67 |
| R-994 | *Valacyclovir Hydrochloride* | IMPURITIES Organic Impurities Procedure 1 (for related compounds E, F, and G) | Line 14 under *Analysis*: Change "The relative response factor values" to: The Relative $R_F$ Values |
| | | | Column 2 in *Impurity Table 1*: Change column heading "Relative Response Factor" to: Relative $R_F$ Value |

| *USP33–NF28 Reissue* Page | Title | CATEGORY Section | Description |
|---|---|---|---|
| ***Second Supplement to USP33–NF28 Reissue*** | | | |
| R-1378 | *Acitretin Capsules* | IMPURITIES Organic Impurities Procedure: Limit of Degradation Products | Line 3: Change subsection head "*Diluent, Mobile phase, System suitability solution, Sample solution,* and *Chromatographic system:*" to: *Diluent, Mobile phase, System suitability solution, Sample solution, Chromatographic system,* and *System suitability:* |
| | | | Row 3 in *Impurity Table 1*: Change the *Relative Retention Time* for 9-*cis* isomer[b] "0.55" to: 1.09 |
| R-1396 | *Cefdinir Capsules* | IMPURITIES Organic Impurities Procedure | Under *Mobile phase*, in the gradient table, under column heading *Time (min)*, row 6: Change "28" to: 38 |

⟨711⟩ Dissolution. Replace this drawing




with:




The *USP 34–NF 29* Errata posting of December 30, 2010, lists a larger than normal number of Errata. A majority of these Errata result from two types of errors: First, as part of a revision to General Chapter 11 USP Reference Standards in *USP 34–NF 29*, the comprehensive list of USP Reference Standards specified in USP and NF monographs and general chapters was eliminated and the remaining information was moved into the monographs. It was discovered that not all information was moved correctly. The information is being restored to the proper monograph using the Errata process. The second error type included the omission of several procedural notes that followed the Reference Standard information and preceded the Identification section in the official text. The missing notes are being restored using the Errata process.

| *USP34–NF29* Page | Title | CATEGORY Section | Description |
|---|---|---|---|
| 7 | *General Notices and Requirements* | 6.40 *Dried, Anhydrous, Ignited, or Solvent-Free Basis* | Line 6: Delete "*Determination*" from the phrase "provided in a test for *Loss on Drying*, or *Water Determination*," |
| 70 | ⟨81⟩ *Antibiotics—Microbial Assays* | *Organisms and Inoculum Test Organisms* | Row 18 in Table 3: add the value "1" to *Staphylococcus aureus* (29737) under the column *Incubation Conditions, Medium.* |
| 535 | ⟨1054⟩ *Biotechnology-Derived Articles—Isoelectric Focusing* | *Introduction* | Line 10: Change "*Biotechnology-Derived Articles—*⟨1057⟩." to: *Biotechnology-Derived Articles—Total Protein Assay* ⟨1057⟩. |
| 1120 | *Echinacea angustifolia* | *USP Reference standards* ⟨11⟩ | Line 2: Change "USP Powdered *Echinacea purpurea* Extract RS" to: USP Powdered *Echinacea angustifolia* Extract RS |
| 1142 | *Garlic Fluidextract* | *USP Reference standards* ⟨11⟩ | Line 2: Change "USP γ-Glutamyl-(*S*)-Allyl-L-Cysteine RS" to: USP *S*-Allyl-L-Cysteine RS |

| *USP34–NF29* Page | Title | CATEGORY Section | Description |
|---|---|---|---|
| 1581 | *Methacrylic Acid Copolymer Dispersion* | ADDITIONAL REQUIREMENTS USP Reference Standards ⟨11⟩ | Delete "USP Methacrylic Acid Copolymer, Type B RS" |
| 1647 | *Propylene Glycol Monocaprylate* | *USP Reference standards* ⟨11⟩ | Lines 2 and 3: Change "Monolaurate" to: Monocaprylate |
| 1969 | *Azithromycin for Injection* | *USP Reference standards* ⟨11⟩ | Add: "USP Desosaminylazithromycin RS" |
| 1981 | *Bacitracin and Polymyxin B Sulfate Topical Aerosol* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Thin-layer chromatographic identification test* ⟨201BNP⟩: [NOTE—Prepare the specimen for the following tests and assays as follows. Maintain the container in the inverted position throughout this procedure. Store the container in a freezer at −70° for 16 to 24 hours. Remove the container from the freezer, promptly puncture the container, and allow the propellant to volatilize. Open the container, and mix the contents.] |
| 2120 | *Calcitonin Salmon* | *USP Reference standards* ⟨11⟩ | Line 5: Change "USP Calcitonin Salmon Related Compound B RS " to: USP Calcitonin Salmon Related Compound B RS (calcitonin salmon-glycine) |
| 2217 | *Cefepime Hydrochloride* | *USP Reference standards* ⟨11⟩ | Add the following under USP Cefepime Hydrochloride System Suitability RS: This is a mixture of cefepime hydrochloride related compound A ([6*R*-[6α,7β(*E*)]]-1-[[7-[[(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium chloride, monohydrochloride, monohydrate; ($C_{19}H_{25}ClN_6O_5S_2 \cdot HCl \cdot H_2O$ ◊ 571.50); cefepime related compound B [6*R-trans*]-7-[[[2-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-4-thiazolyl](methoxyimino)acetyl]amino]-3-(1-methylpyrrolidinium-1-yl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, inner salt; ($C_{25}H_{29}N_9O_7S_3$ ◊ 663.75); and cefepime hydrochloride.and Cefepime hydrochloride. |
| 2219 | *Cefepime for Injection* | *USP Reference standards* ⟨11⟩ | Add the following under USP Cefepime Hydrochloride System Suitability RS: This is a mixture of cefepime hydrochloride related compound A ([6*R*-[6α,7β(*E*)]]-1-[[7-[[(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methylpyrrolidinium chloride, monohydrochloride, monohydrate; ($C_{19}H_{25}ClN_6O_5S_2 \cdot HCl \cdot H_2O$ ◊ 571.50); cefepime related compound B [6*R-trans*]-7-[[[2-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-4-thiazolyl](methoxyimino)acetyl]amino]-3-(1-methylpyrrolidinium-1-yl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, inner salt; ($C_{25}H_{29}N_9O_7S_3$ ◊ 663.75); and cefepime hydrochloride.and Cefepime hydrochloride. |
| 2315 | *Chlorpromazine* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*: [NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2315 | *Chlorpromazine Suppositories* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*: [NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2315 | *Chlorpromazine Hydrochloride* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*: [NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2316 | *Chlorpromazine Hydrochloride Oral Concentrate* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*: [NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |

| *USP34–NF29* Page | Title | CATEGORY Section | Description |
|---|---|---|---|
| 2316 | *Chlorpromazine Hydrochloride Injection* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2317 | *Chlorpromazine Hydrochloride Syrup* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2317 | *Chlorpromazine Hydrochloride Tablets* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the Reference Standard, and solutions containing them by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2399 | *Clonidine Transdermal System* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures avoid the use of tetrahydrofuran stabilized with butylated hydroxytoluene (BHT). In the presence of peroxides, BHT may react with clonidine, producing impurity peaks.] |
| 2466 | *Cytarabine for Injection* | *USP Reference standards* ⟨11⟩ | After line 2, add "USP Endotoxin RS" |
| 2883 | *Fluphenazine Decanoate* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2884 | *Fluphenazine Decanoate Injection* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 2890 | *Flurazepam Hydrochloride* | *USP Reference standards* ⟨11⟩ | Line 1: Change "USP Fluphenazine Enanthate RS"<br>to:<br>USP Flurazepam Hydrochloride RS |
| 2891 | *Flurazepam Hydrochloride Capsules* | *USP Reference standards* ⟨11⟩ | Line 1: Change "USP Fluphenazine Enanthate RS"<br>to:<br>USP Flurazepam Hydrochloride RS |
| 2930 | *Gabapentin* | *USP Reference standards* ⟨11⟩ | Add: USP Gabapentin RS |
| 2941 | *Gadoteridol Injection* | *USP Reference standards* ⟨11⟩ | Line 2: Change "USP Gadoversetamide RS"<br>to:<br>USP Gadoteridol RS |
| 3220 | *Diluted Isosorbide Mononitrate* | *USP Reference standards* ⟨11⟩ | Line 1: Add beneath *USP Isosorbide RS*:<br>[NOTE—The following Reference Standards are dry mixtures of an active component and suitable excipients to permit safe handling. For quantitative applications, calculate the concentration of the active component based on the content stated on the label.] |
| 3221 | *Isosorbide Mononitrate Tablets* | *USP Reference standards* ⟨11⟩ | Line 1: Add beneath *USP Isosorbide RS*:<br>[NOTE—The following Reference Standards are dry mixtures of an active component and suitable excipients to permit safe handling. For quantitative applications, calculate the concentration of the active component based on the content stated on the label.] |
| 3223 | *Isosorbide Mononitrate Extended-Release Tablets* | *USP Reference standards* ⟨11⟩ | Line 1: Add beneath *USP Isosorbide RS*:<br>[NOTE—The following Reference Standards are dry mixtures of an active component and suitable excipients to permit safe handling. For quantitative applications, calculate the concentration of the active component based on the content stated on the label.] |
| 3493 | *Methylphenidate Hydrochloride Extended-Release Tablets* | PERFORMANCE TESTS<br>Dissolution ⟨711⟩ | Row 6, column 2 of table under Test 1: Change<br>"NLT 80"<br>to:<br>NLT 80% |

| *USP34–NF29* Page | Title | CATEGORY Section | Description |
|---|---|---|---|
| 3658 | *Nifedipine Capsules* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>[NOTE—Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenylpyridine derivative. Exposure to UV light leads to the formation of a nitrophenylpyridine derivative. Perform assays and tests in the dark or under golden fluorescent or other low-actinic light. Use low-actinic glassware.] |
| 3803 | *Pancreatin* | *Assay for lipase activity (Fat digestive power)* | Line 1 under *Procedure*: Change "Mix 10.0 mL of *Olive oil substrate*, 8.0 mL of *′*,"<br>to:<br>Mix 10.0 mL of *Olive oil substrate*, 8.0 mL of *Buffer solution*, |
| 3879 | *Perphenazine Injection* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware. |
| 3879 | *Perphenazine Oral Solution* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware. |
| 3880 | *Perphenazine Syrup* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware. |
| 3880 | *Perphenazine Tablets* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware. |
| 3881 | *Perphenazine and Amitriptyline Hydrochloride Tablets* | | Add the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware. |
| 4041 | *Propafenone Hydrochloride* | IMPURITIES<br>Organic Impurities: Procedure | Impurity Table 1: Change row 7 "Any individual, unpsecified impurity"<br>to:<br>Individual unspecified impurities |
| 4117 | *Ramipril Capsules* | ASSAY<br>Procedure | Line 6 under *Chromatographic system*: Change<br>"**Column temperature:** 60°"<br>to:<br>**Temperature:** 60° |
| 4419 | *Thioridazine Oral Suspension* | | Change the following NOTE between *USP Reference standards* ⟨11⟩ and *Identification*:<br>"[NOTE—Conduct this test without exposure to daylight, and with a minimum of exposure to artificial light.]"<br>to:<br>[NOTE—Throughout the following procedures, protect test or assay specimens, the USP Reference Standard, and solutions containing them, by conducting the procedures without delay, under subdued light, or using low-actinic glassware.] |
| 4430 | *Tiagabine Hydrochloride Oral Suspension* | ASSAY<br>Procedure | Line 6 under *Chromatographic system*: Change<br>"**Column**: 3.0-mm × 15-cm; packing L10"<br>to:<br>**Column**: 3.0-mm × 15-cm; 5-µm packing L10 |
| 4585 | *Vincristine Sulfate* | *USP Reference standards* ⟨11⟩ | Line 3: Change "is needed for USP Vincristine Sulfate RS.]"<br>to:<br>is needed for USP Vinblastine Sulfate RS.] |

| ***USP34–NF29*** **Page** | **Title** | **CATEGORY** **Section** | **Description** |
|---|---|---|---|
| 4587 | *Vincristine Sulfate for Injection* | ADDITIONAL REQUIREMENTS<br>USP Reference standards ⟨11⟩ | Line 3: Change<br>"USP Vinblastine Sulfate RS<br>USP Vincristine Sulfate RS [NOTE—No *Loss on drying* determination is needed for USP Vincristine Sulfate RS.]"<br>to:<br>USP Vinblastine Sulfate RS [NOTE—No *Loss on drying* determination is needed for USP Vinblastine Sulfate RS.]<br>USP Vincristine Sulfate RS |
| 4597 | *Sterile Water for Inhalation* | SPECIFIC TESTS<br>Water Conductivity, *Packaged Water* ⟨645⟩ | Change the heading from: "Water Conductivity, *Packaged Water* ⟨645⟩"<br>to:<br>Water Conductivity, *Sterile Water* ⟨645⟩ |
| 4598 | *Sterile Water for Injection* | SPECIFIC TESTS<br>Water Conductivity, *Packaged Water* ⟨645⟩ | Change the heading from: "Water Conductivity, *Packaged Water* ⟨645⟩"<br>to:<br>Water Conductivity, *Sterile Water* ⟨645⟩ |
| 4598 | *Sterile Water for Irrigation* | SPECIFIC TESTS<br>Water Conductivity, *Packaged Water* ⟨645⟩ | Change the heading from: "Water Conductivity, *Packaged Water* ⟨645⟩"<br>to:<br>Water Conductivity, *Sterile Water* ⟨645⟩ |
| 4599 | *Sterile Purified Water* | SPECIFIC TESTS<br>Water Conductivity, *Packaged Water* ⟨645⟩ | Change the heading from: "Water Conductivity, *Packaged Water* ⟨645⟩"<br>to:<br>Water Conductivity, *Sterile Water* ⟨645⟩ |